Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

GSK ADR Aktie

 >GSK ADR Aktienkurs 
34.6 EUR    +0.0%    (Tradegate)
Ask: 34.4 EUR / 440 Stück
Bid: 34.2 EUR / 440 Stück
Tagesumsatz: 29 Stück
Realtime Kurs von 8 bis 22 Uhr!
GSK ADR Aktie über LYNX handeln
>GSK ADR Performance
1 Woche: +4,2%
1 Monat: +10,2%
3 Monate: +0,3%
6 Monate: -1,4%
1 Jahr: -8,0%
laufendes Jahr: +5,5%
>GSK ADR Aktie
Name:  GSK PLC SP. ADR/2 NEW
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US37733W2044 / A3DMHS
Symbol/ Ticker:  GS70 (Frankfurt) / GSK (NYSE)
Kürzel:  FRA:GS70, ETR:GS70, GS70:GR, NYSE:GSK
Index:  -
Webseite:  https://www.gsk.com/
Profil:  GSK plc Sponsored ADR represents the American Depo..
>Volltext..
Marktkapitalisierung:  68438.2 Mio. EUR
Unternehmenswert:  84019.21 Mio. EUR
Umsatz:  37061.44 Mio. EUR
EBITDA:  10808.76 Mio. EUR
Nettogewinn:  4010.66 Mio. EUR
Gewinn je Aktie:  0.98 EUR
Schulden:  20333.35 Mio. EUR
Liquide Mittel:  4216.88 Mio. EUR
Operativer Cashflow:  8527.49 Mio. EUR
Bargeldquote:  0.18
Umsatzwachstum:  9.22%
Gewinnwachstum:  -7.84%
Dividende je Aktie:  1.41 EUR
Dividendenrendite:  4.15%
Dividendenschätzung:  4.33%
Div. Historie:  15.08.25 - 0.36565557€
16.05.25 - 0.37134048€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  GSK ADR, GSK, GLAXOSMITHKLINE, GLAXO
Letzte Datenerhebung:  23.08.25
>GSK ADR Kennzahlen
Aktien/ Unternehmen:
Aktien: 4029.67 Mio. St.
Frei handelbar: 96.39%
Rückkaufquote: 1.36%
Mitarbeiter: 68629
Umsatz/Mitarb.: 0.49 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 9.81%
Bewertung:
KGV: 17.48
KGV lG: 9.1
KUV: 1.93
KBV: 3.97
PEG-Ratio: -
EV/EBITDA: 7.77
Rentabilität:
Bruttomarge: 71.69%
Gewinnmarge: 10.82%
Operative Marge: 17.22%
Managementeffizenz:
Gesamtkaprendite: 5.84%
Eigenkaprendite: 23.47%
 >GSK ADR Anleihen 
Es sind 6 Anleihen zur GSK ADR Aktie bekannt.
>GSK ADR Peer Group

Es sind 601 Aktien bekannt.
 
16.08.25 - 16:15
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK (PR Newswire)
 
NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......
13.08.25 - 17:51
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.08.25 - 22:06
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
 
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million TRELEGY year-to-date sales on......
12.08.25 - 15:18
GSK Aktie: Bewertung weiterhin im Keller (Aktiencheck)
 
Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät die Aktie von GSK plc (ISIN: GB00BN7SWP63, WKN: A3DMB5, Ticker-Symbol: GS71, London Stock Exchange-Symbol: GSK, NASDAQ OTC-Symbol: GLAXF) nach wie vor zu kaufen. [mehr]...
12.08.25 - 07:48
Down 16% from its year high, GSK′s share price looks 68% undervalued to me now despite strong H1 results! (Fool)
 
GSK's share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely underpriced compared to its fair value. The post Down 16% from its year high, GSK's share price looks 68% undervalued to me now despite strong H1 results! appeared first on The Motley Fool UK....
11.08.25 - 23:33
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight (PR Newswire)
 
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a strong pipeline of clinical trials, and growing regulatory approvals. Leading companies such as GlaxoSmithKline, Mirum Pharmaceuticals,......
11.08.25 - 16:01
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK (PR Newswire)
 
NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns......
11.08.25 - 13:42
GSK bid to expand Blujepa label for gonorrhea granted FDA priority review (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 10:01
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 10:00
GSK gepotidacin edges closer to landmark approval for gonorrhoea (ShareCast)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.25 - 09:12
GSK: Gepotidacin Accepted For FDA Priority Review For Uncomplicated Urogenital Gonorrhoea (AFX)
 
LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Monday that the US Food and Drug Administration has accepted for priority review a supplemental New Drug Application for gepoti......
11.08.25 - 08:36
FDA prüft GSK-Mittel Gepotidacin vorrangig gegen Gonorrhoe (Dow Jones)
 
Von Cristina Gallardo DOW JONES--Die US-Arzneimittelbehörde FDA will das Medikament Gepotidacin von GSK vorrangig prüfen um festzustellen, ob es für die Behandlung unkomplizierter urogenitaler ......
10.08.25 - 11:48
Proactive health highlights: GSK, Novo, Futura, Faron, Immupharma, Creo and more (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 23:00
Drugmaker GSK lands £372m in Covid jab pact (DailyMail)
 
The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19....
08.08.25 - 13:12
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 10:12
GSK wins settlement, future royalties in CureVac mRNA patent dispute (Alliance)
 
GSK PLC on Friday said it will receive an upfront payment of $370 million from CureVac BV, following a patent settlement...
08.08.25 - 10:06
Biontech und Curevac: Streit um mRNA-Impfstoffe – GSK kassiert 500 Millionen Dollar (Handelsblatt)
 
In einem Patentstreit um Corona-Impfstoffe zwischen Curevac, Pfizer und Biontech wurde nun ein Vergleich geschlossen. Profitieren soll dabei auch der britische Arzneiriese GSK....
08.08.25 - 09:36
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement (Bloomberg)
 
CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac's former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales....
08.08.25 - 09:12
GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement (AFX)
 
LONDON (dpa-AFX) - British drug major GSK plc (GSK, GSK.L) announced Friday that it will receive an upfront settlement of $370 million from CureVac N.V. following the mRNA patent settlement reache......
07.08.25 - 03:51
The American Academy Of Pediatrics: Mining Children For Profit (ZeroHedge)
 
The American Academy Of Pediatrics: Mining Children For Profit Authored by David Bell via The Brownstone Institute, American healthcare is currently providing us with an excellent lesson in what capitalism looks like in the absence of a moral framework. The biggest losers are America's children... The Union Profiting from Childhood Sickness The American Academy of Pediatrics (AAP), the major professional association of North American pediatricians, has overseen the rising rates of chronic illness and medicating of American children over recent decades. With 67,000 members in the United States, Canada, and Mexico, AAP distinguished itself during Covid-19 for its strident insistence that children's faces should be covered and they should be injected with modified RNA vaccines, despite knowing from early 2020 that severe Covid-19 was very rare in healthy children.  Funded by sources including Moderna, Merck, Sanofi, GSK, Eli Lilly, and other pharmaceutical companies, the AAP's members ...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Politiker verschweigt oft auch das, was er nicht weiß. - Dr. Fritz P. Rinnhofer
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!